REG - Venture Life Group - Directorate Change

Venture LifeAnnouncement

08/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250908:nRSH3044Ya&default-theme=true

RNS Number : 3044Y  Venture Life Group PLC  08 September 2025

8(th) September 2025

 

 

VENTURE LIFE GROUP PLC

 

("Venture Life", "VLG" or the "Group")

 

Directorate Change

 

Venture Life (AIM: VLG), a leader in product innovation, development and
commercialisation within the global consumer healthcare sector, is pleased to
announce the appointment of Mr Peter Jackson to the Board of the Company as
Chief Digital and Technology Officer. Peter's appointment will take effect
from 1 December 2025.

 

Peter is a very experienced global technology leader with over 30 years'
experience delivering transformational Sales, Marketing, ERP, CRM analytics
solutions across FMCG, Consumer Healthcare, High Tech and Media sectors. Peter
has a proven track record of aligning IT strategy with business goals to
deliver measurable growth, operational efficiency and competitive advantage.
He is recognised for building high-performance global teams, forging strong
business partnerships and driving digital innovation in complex, multi-region
environments. Prior to joining VLG, Peter was with McCormick & Company
(part of the McCormick Corporation) as Global VP, Sales & Marketing IT for
over 4 years, and prior to that for 13 years with Johnson & Johnson
Consumer Care, finishing that time as Senior Director, Customer & Sales
IT, EMEA.

 

Jerry Randall, CEO, commented: "We are absolutely delighted that Peter is
joining our Group, as we continue on our journey of transformational change
into a capital light brand focused global consumer healthcare platform,
supporting consumers on their journey for proactive healthy longevity. Peter
has an exceptional track record of aligning IT strategy with business goals in
multi-region organisations, and I am certain that his extensive experience and
expertise will have a dramatic positive effect on our business in the coming
years. Having integrated digital capabilities with advanced AI & robust
data to drive insights is one of our 5 key strategic pillars and having Peter
in the business will significantly enhance our work on this pillar."

 

 

For further information, please contact:

 

Venture Life Group
PLC
                +44 (0) 1344 578004

 

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

 

Cavendish Capital Markets Limited (Nomad and
Broker)
           +44 (0) 20 7720 0500

 

Stephen Keys/George Lawson (Corporate Finance)

Michael Johnson (Sales)

 

About Venture Life (www.venture-life.com (http://venture-life.com) )

 

Venture Life is an international consumer self-care company focused on
commercialising products for the global self-care market. Headquartered in
the UK, the Group's product portfolio includes Balance Activ in the area of
women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel
product ranges for energy and glucose management and hypoglycaemia, plus the
Health & Her product range supporting the hormonal lifecycle.

 

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through health & beauty stores,
pharmacies, grocery multiples and e-commerce channels and are sold globally.
In the UK,  Ireland and the USA these are supplied direct by the company to
retailers, elsewhere they are supplied by the Group's international
distribution partners.

 

 

Regulatory Disclosures

 

Save for his upcoming appointment as a director of the Company, Peter Robert
Jackson, aged 57, does not hold and has not held any other directorships or
partnerships in the past five years.

 

There is no further information on Peter Jackson required to be disclosed
under Schedule Two, paragraph (g) of the AIM Rules for Companies.

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABBGDCXSGDGUR